-
-
Call more information
660-596-2224 -
Anesthesiology September 2024, Vol. 141, A13–A15. Andexanet for factor Xa inhibitor–associated acute intracerebral hemorrhage. N Engl J Med 2024; 390:1745–55. PMID: 38749032. Patients sustaining acute intracerebral hemorrhage on anticoagulants are at increased risk for hematoma expansion. Factor Xa inhibitors are now widely used for chronic anticoagulation, and before the release of andexanet alfa, no specific reversal […]
Read MoreWe are seeking a dedicated anesthesiologist to join our all-anesthesiologist group. Our team will consist of 4 full-time providers and 1 for vacation relief, managing 3 operating rooms. Position Highlights: Zero call for 3 weeks, followed by 1 week of call without daytime work only call after 7 PM therefore you may not work the […]
Read MoreAuthor: Daniel I. Sessler, M.D. Anesthesiology September 2024, Vol. 141, 428–430. Intraoperative mortality is now so low that it is hard to quantify. In contrast, postoperative mortality remains frequent and is arguably the third leading cause of death worldwide. Bleeding-related and cardiovascular complications are the most common causes of 30-day postoperative mortality. Among cardiovascular complications, […]
Read MoreAuthors: Paramita Basu, Ph.D. et al Anesthesiology August 2024. Background Neuropeptide Y (NPY) Y2 receptor (Y2) antagonist BIIE0246 can both inhibit and facilitate nociception. We hypothesized that Y2 function depends on inflammation or nerve injury status. Methods We implemented a battery of behavioral tests in mice of both sexes that received: 1) no injury; 2) […]
Read MoreAuthors: Daniel R. Frei, B.Sc., M.B.Ch.B., Ph.D. et al Anesthesiology September 2024, Vol. 141, 437–439. “[T]he chosen dose (here, Fio2) of the most essential and prevalent drug we use in our practice is basically idiosyncratic.” In 2016, the World Health Organization (Geneva, Switzerland) recommended that adult patients undergoing general anesthesia with tracheal intubation for surgical procedures […]
Read More